ClinicalTrials.gg
CompletedNCT06294275Updated Dec 15, 2025

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

A Phase 1 interventional study of LP-001 Dose 1 (Single) and LP-001 Dose 2 (Single) in Myelodysplastic Syndrome (MDS), sponsored by Longbio Pharma. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Longbio Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Sep 2022, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 117 studies in Myelodysplastic Syndromes with a site in China — 55 open to participants now, 62 under way, 7 of them phase 3. Myelodysplastic Syndromes · China.

Enrollment
56th of 102
68 · median 76
Started
2022
with 8 others
Phase 1
19 of 117
11 open now
Registered
89th of 117
by date

Among the 117 studies in Myelodysplastic Syndromes with a site in China, this one is the 56th largest by enrollment of the 102 interventional ones that give a count, is one of 9 that started in 2022, is one of 19 in phase 1, and was the 89th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

55 of the 117 studies in Myelodysplastic Syndromes with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Myelodysplastic Syndromes with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-001 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-001 and Part 2, multiple ascending dose (MAD).

03

Conditions studied

  • Myelodysplastic Syndrome (MDS)
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females aged 18 through 50 years.
  2. Male subjects with a weight of ≥50 kg, female subjects with a weight of ≥45 kg, and between 19.0 and 26.0 kg/m² (inclusive).
  3. Male subjects and their partners, or female subjects, must agree to use one or more non-pharmacological measures during the trial and up to 6 months after the end of the trial (such as complete abstinence, condoms, intrauterine devices, partner sterilization, etc.), and should have no plans for sperm or egg donation.
  4. The upper limits for (Hb) and hematocrit (HCT) are 165 g/L and 49%, respectively, for males, and 150 g/L and 45%, respectively, for females.
  5. Subjects have a full understanding of the trial's purpose, nature, methods, and potential adverse reactions, voluntarily agree to participate in the trial, and sign the form.
  6. Subjects can communicate effectively with the researchers and can comply with the study protocol as specified.

Exclusion criteria

Exclusion Criteria:

  1. Family history of early-onset coronary artery disease, including first- or second-degree relatives diagnosed with coronary heart disease or angina before the age of 50; any family history of hematological disorders, such as thrombosis or increased clotting risk, or any family history of deep vein thrombosis, pulmonary embolism, stroke, hemolytic anemia, or hemoglobinopathies; family history of hypertension. Alternatively, the subject has a personal medical history of the aforementioned conditions.
  2. Presence of liver or kidney diseases or conditions affecting drug absorption, distribution, metabolism, or excretion, including other medical situations such as surgical procedures, trauma, etc. that may interfere with these processes.
  3. Diagnosed with malignant tumors or having a history of malignant tumors, excluding non-melanoma skin cancer cured for more than 3 years.
  4. testing positive (HIV-Ab), virus (HBV) testing positive (HBsAg or HBcAb), virus (HCV) positive (HCV-RNA), and specific antibodies for syphilis positive, excluding positive results caused by immunization.
  5. Abnormal vital signs (reference normal range: sitting systolic blood pressure 90-139 mmHg, diastolic blood pressure 60-89 mmHg, pulse rate 60-100 beats/min; body temperature 35.4-37.7°C) or abnormal (≥450 ms), or abnormalities in physical examination, laboratory tests, and abdominal ultrasound (as judged by the clinical research doctor).
  6. Clear history of drug allergy or specific reactions (asthma, urticaria, allergic rhinitis, eczematous dermatitis); known allergies to the drug and , or allergies to similar drugs; individuals intolerant to subcutaneous injections or with a history of fainting during needle procedures.
  7. Use of erythropoiesis-stimulating agents or treatment with other biologics within the six months prior to screening.
  8. Participation in any other drug clinical trial within the 3 months prior to screening or within 5 half-lives of any investigational drug from other clinical trials (selecting the longer time period).
  9. Pregnant or lactating women or women with the possibility of becoming pregnant.
  10. Any condition deemed unsuitable for participation in the study by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Cohort 1: LP-001 Dose 1 (Single)

    Single dose administration of LP-001 with dose 1

    Biological: LP-001 Dose 1 (Single)

  • Experimental
    Cohort 2: LP-001 Dose 2 (Single)

    Single dose administration of LP-001 with dose 2

    Biological: LP-001 Dose 2 (Single)

  • Experimental
    Cohort 3: LP-001 Dose 3 (Single)

    Single dose administration of LP-001 with dose 3

    Biological: LP-001 Dose 3 (Single)

  • Experimental
    Cohort 4: LP-001 Dose 4 (Single)

    Single dose administration of LP-001 with dose 4

    Biological: LP-001 Dose 4 (Single)

  • Experimental
    Cohort 5: LP-001 Dose 5 (Single)

    Single dose administration of LP-001 with dose 5

    Biological: LP-001 Dose 5 (Single)

  • Experimental
    Cohort 6: LP-001 Dose 6 (Single)

    Single dose administration of LP-001 with dose 6

    Biological: LP-001 Dose 6 (Single)

  • Placebo comparator
    Cohort 7: Placebo (Single)

    Single dose administration of placebo drug

    Biological: Placebo (Single)

  • Experimental
    Cohort 8: LP-001 Dose 7 (Multiple)

    LP-001 with dose 7 was administered 4 times in total

    Biological: LP-001 Dose 7 (Multiple)

  • Experimental
    Cohort 9: LP-001 Dose 8 (Multiple)

    LP-001 with dose 8 was administered 4 times in total

    Biological: LP-001 Dose 8 (Multiple)

  • Placebo comparator
    Cohort 10: Placebo (Multiple)

    Placebo drug was administered 4 times in total

    Biological: Placebo (Multiple)

Interventions

  • BiologicalLP-001 Dose 1 (Single)

    A single dose of LP-001 (Dose 1) was administered subcutaneously.

  • BiologicalLP-001 Dose 2 (Single)

    A single dose of LP-001 (Dose 2) was administered subcutaneously.

  • BiologicalLP-001 Dose 3 (Single)

    A single dose of LP-001 (Dose 3) was administered subcutaneously.

  • BiologicalLP-001 Dose 4 (Single)

    A single dose of LP-001 (Dose 4) was administered subcutaneously.

  • BiologicalLP-001 Dose 5 (Single)

    A single dose of LP-001 (Dose 5) was administered subcutaneously.

  • BiologicalLP-001 Dose 6 (Single)

    A single dose of LP-001 (Dose 6) was administered subcutaneously.

  • BiologicalPlacebo (Single)

    A single dose of placebo was administered subcutaneously.

  • BiologicalLP-001 Dose 7 (Multiple)

    LP-001 (Dose 7) was administered multiple times subcutaneously.

  • BiologicalLP-001 Dose 8 (Multiple)

    LP-001 (Dose 8) was administered multiple times subcutaneously.

  • BiologicalPlacebo (Multiple)

    Placebo was administered multiple times subcutaneously.

06

What researchers measure

Primary outcomes

  1. Adverse events

    Number of subjects with treatment-related Treatment Emergent Adverse Events (TEAEs).

    Time frame: Observation for 36 days after administration

Secondary outcomes

  1. Time to peak concentration (Tmax) of LP-001

    The time when the blood drug concentration reaches its peak after a single dose of medication.

    Time frame: Observation for 36 days after administration

  2. Maximum concentration (Cmax) of LP-001

    The maximum concentration of LP-001 in the bloodstream after administration.

    Time frame: Observation for 36 days after administration

  3. Elimination half-life (t1/2) of LP-001

    The time required for the concentration of LP-005 in the bloodstream to decrease by half.

    Time frame: Observation for 36 days after administration

  4. Area under the concentration-time curve (AUC0-t) of LP-001

    The time required for the concentration of LP-005 in the bloodstream to decrease by half.

    Time frame: Observation for 36 days after administration

  5. Apparent clearance rate (CL/F) of LP-001

    The ratio of drug clearance to drug concentration, represents the apparent clearance of a drug after administration, adjusted for bioavailability.

    Time frame: Observation for 36 days after administration

  6. Assessment of immunogenicity

    The proportion of anti drug antibody (ADA) positive subjects at different detection time points.

    Time frame: Observation for 36 days after administration

  7. Assessment of hemoglobin (Hb) change

    Concentration of Hemoglobin changes from baseline at various time points of assessment.

    Time frame: Observation for 36 days after administration

  8. Assessment of red blood cell (RBC) count change

    The count of RBC changes from baseline at various time points of assessment.

    Time frame: Observation for 36 days after administration

  9. Assessment of reticulocyte (Rtc) count change

    The count of Rtc changes from baseline at various time points of assessment.

    Time frame: Observation for 36 days after administration

07

Study locations

1 site
  • Shanghai Public Health Clinical Center
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Aug 2023, 11 months.

Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 11 months is below that.

Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Mar 5, 2024
StartActual
Sep 3, 2022
Primary completionActual
Aug 16, 2023
CompletionActual
Aug 16, 2023
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06294275
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Mar 5, 2024
Start date
Sep 3, 2022
Primary completion
Aug 16, 2023
Completion
Aug 16, 2023
Last update
Dec 15, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion